These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 488625)

  • 1. Serum glycoproteins in the liver diseases. VIII. Desialylated glycoproteins in the liver cirrhosis.
    Arima T
    Gastroenterol Jpn; 1979 Aug; 14(4):349-52. PubMed ID: 488625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum glycoproteins in the liver diseases. IV. Alpha-1 acid glycoprotein level in liver cirrhosis.
    Arima T; Motoyama Y; Yamamoto T; Nagata K; Kondo T
    Gastroenterol Jpn; 1977; 12(2):43-6. PubMed ID: 892335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage.
    Marshall JS; Green AM; Pensky J; Williams S; Zinn A; Carlson DM
    J Clin Invest; 1974 Sep; 54(3):555-62. PubMed ID: 4137057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glycoproteins in the liver diseases. V. Desialylated glycoproteins in chronic hepatitis.
    Arima T; Motoyama Y; Yamamoto T; Nagata K; Kondo T; Nagashima H
    Gastroenterol Jpn; 1978; 13(6):503-6. PubMed ID: 748094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis.
    Nomura S; Pittman CS; Chambers JB; Buck MW; Shimizu T
    J Clin Invest; 1975 Sep; 56(3):643-52. PubMed ID: 1159078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases].
    Tomihira M
    Fukuoka Igaku Zasshi; 1991 Jan; 82(1):21-30. PubMed ID: 1708742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ethanol challenge on serum glycoproteins in alcoholic and non-alcoholic liver disease.
    Cobden I; Matthewson K; Carr WP; Dick WC; Record CO
    Alcohol Alcohol; 1987; 22(3):257-63. PubMed ID: 2441717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glycoproteins in the liver diseases. III. Desialylated glycoproteins in the acute hepatitis.
    Arima T; Motoyama Y; Yamamoto T; Nagata K; Kondo T
    Gastroenterol Jpn; 1977; 12(2):39-42. PubMed ID: 892334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum desialylated glycoproteins in patients with hepatobiliary dysfunction.
    Marshall JS; Williams S; Jones P; Hepner GW
    J Lab Clin Med; 1978 Jul; 92(1):30-7. PubMed ID: 96195
    [No Abstract]   [Full Text] [Related]  

  • 10. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal reaction and serum glycoprotein concentration in chronic hepatitis and liver cirrhosis.
    Fehér J; Jakab L; Józsa L; Szilvási I; Papp G
    Acta Morphol Acad Sci Hung; 1975; 23(4):319-26. PubMed ID: 1234831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum inhibitors of desialylated glycoprotein binding to hepatocyte membranes.
    Marshall JS; Williams S
    Biochim Biophys Acta; 1978 Sep; 543(1):41-52. PubMed ID: 101252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE; Miguez C; Rubio M; Bartellini M; Levi D; Podestá A; Niselman V; Terg R
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of resting levels of superoxide anion in the whole blood of patients with decompensated liver cirrhosis.
    Chen MF; Mo LR; Lin RC; Kuo JY; Chang KK; Liao C; Lu FJ
    Free Radic Biol Med; 1997; 23(4):672-9. PubMed ID: 9215813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease.
    Chen CY; Tsai WL; Lin PJ; Shiesh SC
    Clin Chem Lab Med; 2011 Nov; 49(11):1817-21. PubMed ID: 21851314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
    Yang X; Li J; Zhou L; Liu J; Wang J; Lu W
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):396-403. PubMed ID: 24569820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts.
    Koruk M; Onuk MD; Akçay F; Savas MC
    Hepatogastroenterology; 2002; 49(48):1645-8. PubMed ID: 12397754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of thyroid hormones in liver diseases.
    Yamanaka T; Ido K; Kimura K; Saito T
    Clin Chim Acta; 1980 Feb; 101(1):45-55. PubMed ID: 7357737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.